Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Dose escalation of a curcuminoid formulation.

Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE.

BMC Complement Altern Med. 2006 Mar 17;6:10.

2.

Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.

Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP.

Clin Cancer Res. 2001 Jul;7(7):1894-900.

3.

Pharmacokinetics and pharmacodynamics of curcumin.

Sharma RA, Steward WP, Gescher AJ.

Adv Exp Med Biol. 2007;595:453-70. Review.

PMID:
17569224
4.

Curcumin: the story so far.

Sharma RA, Gescher AJ, Steward WP.

Eur J Cancer. 2005 Sep;41(13):1955-68. Review.

PMID:
16081279
5.

Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.

Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP.

Clin Cancer Res. 2004 Oct 15;10(20):6847-54.

6.

Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis.

Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40.

7.

Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment.

Basnet P, Skalko-Basnet N.

Molecules. 2011 Jun 3;16(6):4567-98. doi: 10.3390/molecules16064567. Review.

8.

Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.

Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T.

Cancer Chemother Pharmacol. 2012 Jan;69(1):65-70. doi: 10.1007/s00280-011-1673-1. Epub 2011 May 21.

PMID:
21603867
9.

Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.

Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5.

10.

Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers.

Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG.

J Agric Food Chem. 2010 Feb 24;58(4):2095-9. doi: 10.1021/jf9024807.

PMID:
20092313
12.

Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies.

Epstein J, Sanderson IR, Macdonald TT.

Br J Nutr. 2010 Jun;103(11):1545-57. doi: 10.1017/S0007114509993667. Epub 2010 Jan 26. Review.

PMID:
20100380
13.

Curcumin for chemoprevention of colon cancer.

Johnson JJ, Mukhtar H.

Cancer Lett. 2007 Oct 8;255(2):170-81. Epub 2007 Apr 19.

PMID:
17448598
14.

Clinical studies with curcumin.

Hsu CH, Cheng AL.

Adv Exp Med Biol. 2007;595:471-80. Review.

PMID:
17569225
16.

Systemic delivery of curcumin: 21st century solutions for an ancient conundrum.

Bisht S, Maitra A.

Curr Drug Discov Technol. 2009 Sep;6(3):192-9. Epub 2009 Sep 1. Review.

PMID:
19496751
17.

Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.

Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, Sharma SK, Cross MR, Dutt C.

Clin Drug Investig. 2009;29(9):559-75. doi: 10.2165/11315260-000000000-00000.

PMID:
19663519
18.

Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.

Palma-Aguirre JA, Villalpando-Hernández J, Novoa-Heckel G, Oliva I, Cariño L, López-Bojórquez E, Burke-Fraga V, Namur S, González-de la Parra M.

Clin Ther. 2009 Feb;31(2):399-410. doi: 10.1016/j.clinthera.2009.02.002.

PMID:
19302912
19.

Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).

Graham JS, Plummer R, McCoy C, Kowal K, Wiesinger H, Detjen K, Calvert H, Wiedenmann B, Cassidy J.

Eur J Cancer. 2008 Oct;44(15):2162-8. doi: 10.1016/j.ejca.2008.06.006. Epub 2008 Jul 22.

PMID:
18653327
20.

Curcumin therapeutic promises and bioavailability in colorectal cancer.

Shehzad A, Khan S, Shehzad O, Lee YS.

Drugs Today (Barc). 2010 Jul;46(7):523-32. doi: 10.1358/dot.2010.46.7.1509560. Review.

PMID:
20683505
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk